6 February 2019 – Takis publishing data on personalized neoantigen vaccine platform
We are proud to announce the first POC data achieved in advanced preclinical models with our personalized vaccine platform based on NeoAntigen Identification/DNA Electroporation and published on Journal of Experimental & Clinical Cancer Research.
We have developed different neoantigen minigene vaccine vectors to determine the rules for a successful neoantigen cancer vaccine delivered by plasmid DNA and electroporation. We found that a strong poly-functional and poly-specific immune response was observed with high affinity neoantigens. Our pipeline - from the selection of neoantigens to vaccine design – was also applied to a new model of patient derived tumor xenograft resulting in therapeutic treatment.
These results suggest a feasible strategy for a neoantigen cancer vaccine that is simple and applicable for clinical developments.
Read the full article: https://doi.org/10.1186/s13046-019-1084-4